4.5 Article

Clinical Utility of Early Improvement to Predict Response or Remission in Acute Mania: Focus on Olanzapine and Risperidone

Journal

JOURNAL OF CLINICAL PSYCHIATRY
Volume 72, Issue 9, Pages 1236-1241

Publisher

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.09m05874yel

Keywords

-

Funding

  1. NARSAD
  2. National Institutes of Health
  3. Takeda
  4. US Department of Defense
  5. Health Resources Services Administration
  6. National Institute of Mental Health
  7. Abbott
  8. Abbott, AstraZeneca
  9. Bristol-Myers Squibb
  10. Cephalon
  11. Cleveland Foundation
  12. Eli Lilly
  13. Eli Lilly, GlaxoSmithKline
  14. Janssen
  15. Repligen
  16. Stanley Medical Research Institute
  17. Wyeth
  18. AstraZeneca
  19. Bristol-Myers
  20. Squibb
  21. France Foundation
  22. GlaxoSmithKline
  23. Johnson Johnson
  24. Merck
  25. Pfizer
  26. Sanofi-Aventis
  27. Schering-Plough
  28. Solvay
  29. Eli Lilly and Company, Indianapolis, Indiana
  30. Case Western Reserve University, Cleveland, Ohio

Ask authors/readers for more resources

Objective: To evaluate early improvement associated with atypical antipsychotic treatment as a predictor of later response or remission among patients experiencing an acute manic or mixed episode without psychotic features. Method: A post hoc analysis was performed on data from a 3-week, randomized, double-blind clinical trial of olanzapine (N = 147) or risperidone (N = 127) to treat inpatients aged 18-70 years meeting DSM-IV criteria for bipolar I disorder. Early improvement, measured as percent change >= 25% and >= 50% cut points) in the Young Mania Rating Scale (YMRS) total score, was assessed after 2 days and 1 week of treatment. Receiver operating characteristic curves, sensitivity and specificity, and positive and negative predictive values were calculated to determine whether early improvement predicted endpoint (week 3) response or remission. The study was conducted from July 2001 through June 2002. Results: Among 234 patients with >= 25% reduction in YMRS total score at week one, 167 (71.4%) responded and 121 (51.7%) remitted at endpoint. Of the 40 patients with < 25% improvement, 25% (n = 10) responded and 5% (n = 2) remitted at endpoint. A total of 157 patients had a >= 50% reduction in week 1 YMRS total score, of whom 132 (84.1%) responded and 101(64.3%) remitted at endpoint. Of the 117 patients with < 50% improvement, 45(38.5%) responded and 22(18.8%) remitted at endpoint. Conclusions: Improvement in manic or mixed symptoms at week 1 appears to be a good predictor of treatment outcome. Patients not having sufficient improvement (< 25% reduction in YMRS score) were less likely to reach response or remission by week 3. Patients who achieved response by week 1 (>= 50% reduction in YMRS score) were likely to remain responders at endpoint. These data suggest the potential to assess benefit in the treatment of manic or mixed symptoms within 1 week of initiating olanzapine or risperidone. J Clin Psychiatry 2011;72(9):1236-1241 (C) Copyright 2011 Physicians Postgraduate Press, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available